Dovonex Psoriasis 50 microgram/g ointment
Product Information *
Company:
LEO PharmaStatus:
No Recent UpdateActive Ingredients :
*Additional information is available upon request
Legal Category:
Supply through pharmacy only
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 06 July 2020
File name
ie-mockup-pl dovonex psoriasis excip_1594025427.pdf
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 06 July 2020
File name
ie-spc clean dovonex psoriasis_1594024816.pdf
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
- In section 2 the quantity of propylene glycol has been added
- In section 4.8 the reporting of side effects statement has been updated in accordance with the latest version of Annex 5
Updated on 13 February 2020
File name
ie-pl-dovonex psoriasis ointment-paraffin_1581590509.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 6 - date of revision
- Addition of information on alternative format leaflets
Updated on 07 December 2016
Reasons for updating
- Change to section 10 - Date of revision of the text
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Section 5.1 and 10 updated as follows;
5.1 Pharmacodynamic properties
ATC Code: D05A X02
Pharmacotherapeutic group: Other antipsoriatics for topical use
Calcipotriol is a vitamin D derivative. In vitro data suggest that calcipotriol induces differentiation and suppresses proliferation of keratinocytes. This is the proposed basis for its effect in psoriasis. A clinical improvement usually starts to become apparent after two weeks’ treatment.
10 DATE OF REVISION OF THE TEXT
April 2016 December 2016
Updated on 07 December 2016
Reasons for updating
- New SPC for new product
Legal category:Supply through pharmacy only
Updated on 27 June 2016
Reasons for updating
- Change to warnings or special precautions for use
- Change to date of revision
Updated on 27 June 2016
File name
PIL_16733_458.pdf
Reasons for updating
- New PIL for new product
Updated on 17 May 2016
Reasons for updating
- New SPC for new product
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 13 May 2016
Reasons for updating
- New PIL for new product